What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Omixon Holotype Early Access Program Featured at ASHI Annual Meeting 2015

Omixon announce today that Holotype HLA™ and other Omixon products will be featured in four oral presentations and 12 poster presentations at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Savannah, Georgia. Additionally, in the Tuesday …more

By kriszta.katona 0 comments

Omixon Symposium at APHIA in Bangkok, Thailand

Join us for the upcoming Omixon Symposium, “Introduction to Holotype HLA™ and EAP Success“, our very first event at APHIA in Bangkok!   Date: Wednesday, October 14, 2015 Time: 1:00pm – 1:30pm ICT Venue: Mandarin Hotel, Bangkok Content Welcome & …more

By kriszta.katona 0 comments